Aurobindo Pharma Ltd Stock Price Today (NSE: AUROPHARMA)
Fundamental Score
Aurobindo Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Aurobindo Pharma Ltd share price today is ₹1462.30, down 0.09% on NSE/BSE as of 5 June 2026. Aurobindo Pharma Ltd (AUROPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹70.80K (Cr). The 52-week high for AUROPHARMA share price is ₹1550.00 and the 52-week low is ₹1016.10. At a P/E ratio of 20.69x, AUROPHARMA is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.08% and a debt-to-equity ratio of 0.22.
Aurobindo Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Aurobindo Pharma Ltd share price chart: 1.18% return over the past month. 52-week high ₹1550.00, 52-week low ₹1016.10.
Aurobindo Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1436.90 | ₹1446.50 | ₹1415.10 | ₹1429.20 | 10.66L (Cr) | |
| ₹1426.40 | ₹1449.90 | ₹1421.00 | ₹1433.70 | 13.85L (Cr) | |
| ₹1435.90 | ₹1453.40 | ₹1411.00 | ₹1426.40 | 24.35L (Cr) | |
| ₹1463.00 | ₹1473.00 | ₹1428.50 | ₹1435.90 | 7.92L (Cr) | |
| ₹1450.00 | ₹1467.80 | ₹1449.30 | ₹1461.20 | 9.51L (Cr) | |
| ₹1455.20 | ₹1465.00 | ₹1428.00 | ₹1454.60 | 26.84L (Cr) | |
| ₹1520.00 | ₹1520.00 | ₹1445.80 | ₹1463.50 | 30.39L (Cr) | |
| ₹1523.00 | ₹1550.00 | ₹1515.50 | ₹1546.70 | 10.14L (Cr) | |
| ₹1510.10 | ₹1539.00 | ₹1505.10 | ₹1517.50 | 10.69L (Cr) | |
| ₹1500.50 | ₹1530.00 | ₹1499.80 | ₹1512.80 | 15.39L (Cr) |
Aurobindo Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1426.40 | ₹1449.90 | ₹1415.10 | ₹1429.20 | +0.20% | |
| ₹1398.00 | ₹1550.00 | ₹1367.00 | ₹1426.40 | +2.03% | |
| ₹1332.20 | ₹1459.50 | ₹1266.10 | ₹1389.50 | +4.30% | |
| ₹1186.20 | ₹1330.00 | ₹1179.80 | ₹1304.40 | +9.96% | |
| ₹1172.10 | ₹1250.90 | ₹1106.00 | ₹1220.40 | +4.12% | |
| ₹1190.00 | ₹1270.80 | ₹1116.20 | ₹1207.70 | +1.49% | |
| ₹1229.00 | ₹1240.70 | ₹1160.50 | ₹1183.00 | -3.74% | |
| ₹1142.90 | ₹1249.90 | ₹1120.00 | ₹1226.70 | +7.33% | |
| ₹1086.90 | ₹1155.80 | ₹1066.80 | ₹1138.90 | +4.78% | |
| ₹1022.80 | ₹1138.00 | ₹1016.10 | ₹1083.90 | +5.97% | |
| ₹1142.00 | ₹1144.00 | ₹1020.00 | ₹1027.90 | -9.99% | |
| ₹1137.10 | ₹1197.00 | ₹1100.00 | ₹1139.80 | +0.24% |
AI Research Briefing
Powered by Gemini · 2026-04-08
Aurobindo's buyback is a band-aid on a generics business facing pricing pressure; look for pipeline catalysts, not financial engineering.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Aurobindo Pharma's board approved a share buyback on April 6, 2026, at , a 10% premium to the then-current market price. The buyback involves up to 54,23,728 shares, approximately 0.93% of the total paid-up equity. April 17, 2026, is the record date for determining shareholder eligibility.
CORE STORY (THE REAL GAME)
Shareholder value play. Aurobindo is using excess cash to boost EPS via buyback, signaling confidence despite generic pricing headwinds. This isn't about innovation, it's about financial engineering.
- ₹800 Cr buyback approved
- Q3 profit up 8% YoY
- Solar acquisition extended
- Successful ANDA filings in US
- New drug approvals in Europe
- Faster-than-expected integration of Zentiva acquisition (2025)
- Generics pricing pressure
- US regulatory risk
- High promoter pledging at 17.5%
DII increased stake by 0.67%, FII decreased by 0.17% — mixed signals.
Indian pharma exports are rising, but US tariff risks loom.
Yes — ₹4214.84 Cr Free Cash Flow 5Y.
Near-term: Buyback provides support. Mid-term: US generics pricing and pipeline execution are key.
Primary Thesis Risk
US generics pricing pressure will erode profitability despite buyback.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Aurobindo Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aurobindo Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AUROPHARMA across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (19.25%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 20.69 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Conservative Debt Levels (D/E: 0.22)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (12.77x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹4214.84 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 41.81%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
2 factors identified
Weak Earnings Growth (4.05% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (3.87% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Aurobindo Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Aurobindo Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Aurobindo Pharma LtdAurobindo Pharm...Selected✓ AUROPHARMA • 524804 | 28.8/100 | ₹1462.30₹1462 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Abbott India LtdAbbott India Lt... ABBOTINDIA • 500488 | 65/100 | ₹27735.00₹27735 | ₹63358.16₹63358.16 | 41.99Average 42.0 Average | 35.68%Excellent 35.68% Excellent | 46.25%Excellent 46.25% Excellent | 0.05Excellent 0.1 Excellent | 18.98%Excellent 18.98% Excellent | 9.38%Good 9.38% Good | 1.59% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Aurobindo Pharma Ltd PE Ratio History
Historical price-to-earnings ratio for AUROPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹59.81 | ₹1183.00 | 19.8x |
| FY 2024 | ₹54.16 | ₹1334.50 | 24.6x |
| FY 2023 | ₹32.90 | ₹1084.00 | 32.9x |
| FY 2022 | ₹45.19 | ₹438.30 | 9.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Aurobindo Pharma Ltd Dividend History
Annual cash dividends paid by AUROPHARMA — dividend yield 0.33%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1.04 Cr |
| FY 2024 | ₹263.64 Cr |
| FY 2023 | ₹439.53 Cr |
| FY 2022 | ₹263.70 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Aurobindo Pharma Ltd Quarterly Performance
Latest quarterly metrics for AUROPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
6.28%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
3.80%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
6.55%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
3.87%
Compounded annual net profit growth over 5 years
Aurobindo Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AUROPHARMA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Aurobindo Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Aurobindo Pharma Ltd (AUROPHARMA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Aurobindo Pharma Ltd
About AUROPHARMA (Aurobindo Pharma Ltd)
Aurobindo Pharma Ltd is a global pharmaceutical powerhouse, deeply rooted in the development and manufacturing of a diverse range of healthcare solutions. With a commitment to inno...vation and quality, the company focuses on delivering accessible medicines to patients worldwide. Their broad portfolio encompasses both finished drug formulations and active pharmaceutical ingredients, catering to a variety of therapeutic needs. From cutting-edge manufacturing facilities to a robust research and development infrastructure, Aurobindo Pharma strives to meet the ever-evolving demands of the global healthcare landscape. They operate with a global vision, aiming to expand their reach and impact on patient well-being through strategic partnerships and a dedication to excellence. Aurobindo Pharma specializes in crafting complex generic medications and crucial APIs, ensuring a steady supply of high-quality pharmaceutical products. The company's manufacturing prowess spans various dosage forms, including tablets, capsules, injectables, and inhalers, demonstrating their versatility and commitment to providing comprehensive treatment options. They possess a keen understanding of intricate chemical processes and advanced drug delivery systems. Their API business forms a cornerstone, supplying essential ingredients for numerous medications globally, further solidifying their position within the pharmaceutical ecosystem. This commitment extends to continuous improvement in manufacturing efficiency, sustainability, and adherence to the most stringent regulatory standards. Aurobindo Pharma’s therapeutic focus covers a wide spectrum of medical needs, reflecting their dedication to addressing diverse health challenges. Their offerings include medications targeting cardiovascular ailments, neurological disorders, infectious diseases, and metabolic conditions, among others. By investing in research and development, they strive to create innovative and effective treatments that improve patient outcomes and quality of life. Their dedication to research extends to the development of biosimilars, offering affordable alternatives to complex biologic drugs. This multifaceted approach underscores Aurobindo Pharma's commitment to healthcare accessibility and their mission to serve as a reliable provider of essential medicines to communities around the globe.
Company Details
Key Leadership
Corporate Events
Latest News
AUROPHARMA Share Price: Frequently Asked Questions
What is the current share price of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd (AUROPHARMA) trades at ₹1462.30 on NSE and BSE. Market cap ₹70.80K (Cr). Educational data only.
What is the P/E ratio of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd has a P/E of 20.69x vs industry average 31.77x.
What is the Bull Run score for Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd has a Bull Run score of 28.8/100 based on 25+ financial parameters.
Does Aurobindo Pharma Ltd pay dividends?
Aurobindo Pharma Ltd has a dividend yield of 0.33%. Past dividends don't guarantee future payments.
What is the ROE of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd has ROE of 11.08%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd has debt-to-equity of 0.22.
Is Aurobindo Pharma Ltd a good investment?
Bull Run gives Aurobindo Pharma Ltd a score of 28.8/100. This is not investment advice — consult a SEBI-registered advisor.